Evaluating miRNA Profiling Platforms for Plasma Samples
Author Information
Author(s): Steffen G. Jensen, Philippe Lamy, Mads H. Rasmussen, Marie S. Ostenfeld, Lars Dyrskjøt, Torben F. Ørntoft, Claus L. Andersen
Primary Institution: Department of Molecular Medicine (MOMA), Aarhus University Hospital-Skejby, Denmark
Hypothesis
The study aims to evaluate the performance of three commercial miRNA quantification platforms for detecting low-abundance miRNAs in plasma samples.
Conclusion
The miRCURY platform is superior for profiling clinical samples with low miRNA abundance due to its better sensitivity and linearity.
Supporting Evidence
- The miRCURY platform showed better sensitivity and linearity than the TaqMan platform at low miRNA levels.
- Both qRT-PCR based platforms performed well at high miRNA levels.
- The GeneChip platform failed to produce reliable signals at the input levels studied.
Takeaway
This study tested different tools to measure tiny molecules called miRNAs in blood, finding one tool works better when there are fewer miRNAs.
Methodology
The study used synthetic miRNA samples and plasma RNA samples spiked with synthetic miRNAs to assess the performance of three platforms.
Potential Biases
Potential for false positives due to sequence homology among miRNAs.
Limitations
The GeneChip platform was excluded from further assessment due to its limited sensitivity with low RNA input levels.
Participant Demographics
Patients diagnosed with Colorectal Cancer (CRC).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website